Soligenix enters partnership with Sterling Pharma

Soligenix announced that it has established a partnership agreement with Sterling Pharma Solutions to optimize and implement a commercially viable, scalable production technology for synthetic hypericin. Synthetic hypericin, the active ingredient in the topical drug product formulations HyBryte and SGX302 being developed for the treatment of cutaneous T-cell lymphom and psoriasis, respectively, is a potent photosensitizer that is topically applied to skin lesions. Soligenix and Sterling are currently working to transfer and optimize the manufacturing processes and analytics to enable GMP manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.